HUP0001136A2 - Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények - Google Patents

Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények

Info

Publication number
HUP0001136A2
HUP0001136A2 HU0001136A HUP0001136A HUP0001136A2 HU P0001136 A2 HUP0001136 A2 HU P0001136A2 HU 0001136 A HU0001136 A HU 0001136A HU P0001136 A HUP0001136 A HU P0001136A HU P0001136 A2 HUP0001136 A2 HU P0001136A2
Authority
HU
Hungary
Prior art keywords
remedies
antibody
pharmaceutical preparations
except
cell neoplasms
Prior art date
Application number
HU0001136A
Other languages
English (en)
Inventor
Yasuo Koishihara
Yasushi Yoshimura
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HUP0001136A2 publication Critical patent/HUP0001136A2/hu
Publication of HUP0001136A3 publication Critical patent/HUP0001136A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Atalálmány limfatikűs tűmőrők (a mielóma kivételével) kezeléséreszőlgáló gyógyszerkészítményekre vőnatkőzik, melyek hatóanyagként egyantitestet tartalmaznak, amely specifikűsan kötődik a SEQ ID NO: 1-benbeműtatőtt aminősavszekvenciával rendelkező fehérjéhez, és citőtőxikűsaktivitással rendelkezik. A találmány szerinti gyógyszerkészítmények,melyekben az antitest ADCC vagy CDC aktivitással rendelkezik,felhasználhatók mind T-sejt-tűmőrők, mind B-sejt-tűmőrők (kivéve amielómát) terápiájában. ŕ
HU0001136A 1997-02-12 1998-02-12 Remedies for lymphocytic tumors HUP0001136A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4141097 1997-02-12

Publications (2)

Publication Number Publication Date
HUP0001136A2 true HUP0001136A2 (hu) 2000-08-28
HUP0001136A3 HUP0001136A3 (en) 2002-02-28

Family

ID=12607597

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001136A HUP0001136A3 (en) 1997-02-12 1998-02-12 Remedies for lymphocytic tumors

Country Status (20)

Country Link
US (2) US6503510B2 (hu)
EP (1) EP0997152B1 (hu)
KR (2) KR100655979B1 (hu)
CN (1) CN1191855C (hu)
AT (1) ATE297219T1 (hu)
AU (1) AU724133B2 (hu)
BR (1) BR9811094A (hu)
CA (1) CA2280875C (hu)
DE (1) DE69830492T2 (hu)
ES (1) ES2241114T3 (hu)
HK (1) HK1026368A1 (hu)
HU (1) HUP0001136A3 (hu)
IL (1) IL131381A0 (hu)
NO (1) NO993866L (hu)
PL (1) PL190065B1 (hu)
RU (1) RU2177805C2 (hu)
SK (1) SK110099A3 (hu)
TR (1) TR199901949T2 (hu)
UA (1) UA65561C2 (hu)
WO (1) WO1998035698A1 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ATE462975T1 (de) * 1998-02-25 2010-04-15 Chugai Pharmaceutical Co Ltd Verfahren zum immunochemischen testen des anti- hm1.24-antikörpers
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
DE60141297D1 (de) * 2000-12-28 2010-03-25 Kyowa Hakko Kirin Co Ltd Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
EP2336149A1 (en) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US7888478B2 (en) * 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) * 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
WO2003072068A2 (en) * 2002-02-27 2003-09-04 University Of South Carolina Targeted immunotherapy of acute lymphoblastic leukemia (all)
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
WO2005014651A1 (ja) * 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
JP4794303B2 (ja) * 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤
TWI468514B (zh) * 2004-10-26 2015-01-11 Chugai Pharmaceutical Co Ltd Sugar chain modified phosphatidylinositol glyphosyl 3 antibody
US20080299128A1 (en) * 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
CN104031150A (zh) 2007-10-16 2014-09-10 Sbi生物技术有限公司 抗bst2抗体
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US9123149B2 (en) * 2013-03-15 2015-09-01 Columbia Insurance Company Expert color system for color selection with color harmony and color emotion intelligence
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
EP0972524A4 (en) * 1997-02-28 2001-03-28 Chugai Pharmaceutical Co Ltd LYMPHOCYTE ACTIVATION INHIBITORS
RU2221809C2 (ru) * 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
CN101073667B (zh) * 1997-10-14 2013-11-06 中外制药株式会社 淋巴细胞肿瘤抗体的增强剂

Also Published As

Publication number Publication date
KR100655979B1 (ko) 2006-12-08
UA65561C2 (uk) 2004-04-15
DE69830492T2 (de) 2006-03-16
RU2177805C2 (ru) 2002-01-10
UA65561A (en) 2000-08-15
KR20030097614A (ko) 2003-12-31
DE69830492D1 (de) 2005-07-14
ATE297219T1 (de) 2005-06-15
PL335140A1 (en) 2000-04-10
EP0997152B1 (en) 2005-06-08
CA2280875C (en) 2005-07-05
KR20000070989A (ko) 2000-11-25
BR9811094A (pt) 2000-07-18
US6503510B2 (en) 2003-01-07
NO993866L (no) 1999-10-11
EP0997152A1 (en) 2000-05-03
CN1250381A (zh) 2000-04-12
PL190065B1 (pl) 2005-10-31
IL131381A0 (en) 2001-01-28
ES2241114T3 (es) 2005-10-16
SK110099A3 (en) 2000-08-14
CN1191855C (zh) 2005-03-09
EP0997152A4 (en) 2001-04-18
HK1026368A1 (en) 2000-12-15
US20020037288A1 (en) 2002-03-28
AU724133B2 (en) 2000-09-14
TR199901949T2 (xx) 2000-01-21
US20030113334A1 (en) 2003-06-19
WO1998035698A1 (fr) 1998-08-20
AU5956398A (en) 1998-09-08
HUP0001136A3 (en) 2002-02-28
NO993866D0 (no) 1999-08-11
CA2280875A1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
MXPA05005330A (es) Composiciones y formulaciones de gastrina, y metodos de uso y preparacion.
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
GB2340121B (en) Delivery system
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
SE9704546D0 (sv) Novel compounds
TR199901433T2 (xx) Pirolo$3,4-D] pirimidinon t�revleri ve bunlar�n ila� olarak kullan�mlar�.
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
KR910002899A (ko) 혈조절 펩타이드
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
DK0811068T3 (da) Humane DNase I varianter
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa
ATE313323T1 (de) Pharmazeutische zubereitungen
RU2001114528A (ru) Рецепторное тело, специфически связывающее TIE-2 лиганд, выделенная молекула нуклеиновой кислоты, плазмида, фармацевтическая композиция, способ предотвращения или ослабления неоваскуляризации у млекопитающего
DE50013908D1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie
SE9704835D0 (sv) New compound